Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Emily Garrett-Pruett

Nurse Practitioner, Psychiatric/Mental Health Midlothian, VA Nurse Practitioner

NPI 1952503690 CMS profile 11147999

15521 Midlothian Tpke Ste 105, Midlothian, VA 23113

Open in the dashboard

General payments

$3,424

212 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emily Garrett-Pruett of Midlothian, VA is reported in the CMS Open Payments database as having received $3,424 across 212 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23 1
2024 General $233 14
2023 General $1,121 62
2022 General $1,185 65
2021 General $862 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Garrett-Pruett
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Emily Garrett-Pruett were reported at $23. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Emily Garrett-Pruett Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $862 $166 $54–$482 $132
2022 $1,185 $195 $66–$559 $149
2023 $1,121 $233 $82–$673 $160
2024 $233 $236 $84–$688 $164
2025 $23 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alkermes, Inc. $709 31 payments
  2. Teva Pharmaceuticals USA, Inc. $671 38 payments
  3. Janssen Pharmaceuticals, Inc $378 29 payments
  4. Otsuka America Pharmaceutical, Inc. $351 24 payments
  5. AbbVie, Inc. $312 22 payments
  6. Sunovion Pharmaceuticals Inc. $228 25 payments
  7. ITI, Inc. $178 8 payments
  8. Neurocrine Biosciences, Inc. $158 9 payments
  9. Indivior Inc. $132 8 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $130 8 payments
  11. Other $177 10 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,418 211 payments
  2. Education $6 1 payment
Products named General payments · program years 2021–2025
  1. LYBALVI Cns $533 24 payments
  2. ARISTADA Cns $514 26 payments
  3. ARISTADA Cns $514 26 payments
  4. LYBALVI Cns $374 16 payments
  5. Austedo XR $355 23 payments
  6. ARISTADA INITIO $354 18 payments
  7. VRAYLAR $312 22 payments
  8. ARISTADA Cns $311 13 payments
  9. ARISTADA Cns $311 13 payments
  10. SPRAVATO $284 22 payments
  11. Other $2,197 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

5,648

Median for Nurse Practitioner: 389

Drug cost

$3,291,177

Median for Nurse Practitioner: $21,885

Branded share of claims

21.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 266 $1,494,026
Invega Sustenna Paliperidone Palmitate Brand 261 $863,716
Uzedy Risperidone Brand 41 $159,496
Aristada Aripiprazole Lauroxil Brand 40 $136,413
Austedo Xr Titration Kt(Wk1-4) Deutetrabenazine Brand 18 $130,817
Ingrezza Valbenazine Tosylate Brand 33 $121,191
Abilify Maintena Aripiprazole Brand 41 $116,711
Rexulti Brexpiprazole Brand 142 $109,871
Olanzapine Generic 332 $21,891
Chlorpromazine Hcl Generic 150 $21,871

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$6,241

Medicare's payments for the services billed

Medicare patients

307

Average age 66

Services billed

318

119 women, 188 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Diabetes 49%
Alzheimer's or dementia 47%
COPD 40%
Arthritis 37%
Ischemic heart disease 24%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $212
$212 284 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $20
$20 41 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record